Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Caitlin Schafer"'
Autor:
Mathieu Lupien, Yulia Jitkova, Michael Mullokandov, Helen Loo Yau, Rima Al-awar, James R. Hawley, Rose Hurren, Troy Ketela, S. Kim, Veronique Voisin, Neil MacLean, Daniel D. De Carvalho, Mark D. Minden, Geethu E. Thomas, Val A. Fajardo, Ahmed Aman, Zhenyue Hao, Zaza Khuchua, G. Wei Xu, Gary D. Bader, Richard P. Bazinet, Juan J. Aristizabal Henao, Mingjing Xu, Paul J. LeBlanc, Ayesh K. Seneviratne, Steven M. Claypool, Steven M. Chan, Xiaoming Wang, Atan Gross, Aaron D. Schimmer, Ken D. Stark, David Sharon, Raphaël Chouinard-Watkins, Danny V. Jeyaraju, Caitlin Schafer, Marcela Gronda
Summary Tafazzin (TAZ) is a mitochondrial transacylase that remodels the mitochondrial cardiolipin into its mature form. Through a CRISPR screen, we identified TAZ as necessary for the growth and viability of acute myeloid leukemia (AML) cells. Genet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43b74e60e809d7c98db8697836fef410
https://europepmc.org/articles/PMC7137093/
https://europepmc.org/articles/PMC7137093/
Autor:
Caitlin Schafer, Vicky Moore, Nupur Dasgupta, Sabzali Javadov, Jeanne F. James, Alexander I. Glukhov, Arnold W. Strauss, Zaza Khuchua
Publikováno v:
Frontiers in Pharmacology, Vol 9 (2018)
Frontiers in Pharmacology
Frontiers in Pharmacology
Aim: Tafazzin knockdown (TazKD) in mice is widely used to create an experimental model of Barth syndrome (BTHS) that exhibits dilated cardiomyopathy and impaired exercise capacity. Peroxisome proliferator-activated receptors (PPARs) are a group of nu
Autor:
Mindong Ren, John L. Jefferies, Yan Huang, Frédéric M. Vaz, Alexander V. Glukhov, Victoria Moore, Colin K.L. Phoon, Corey Powers, Sabzali Javadov, Arnold W. Strauss, Jeanne James, Zaza Khuchua, Caitlin Schafer
Publikováno v:
Orphanet Journal of Rare Diseases
Orphanet journal of rare diseases, 12(1). BioMed Central
Orphanet journal of rare diseases, 12(1). BioMed Central
Background The PGC-1α/PPAR axis has been proposed as a potential therapeutic target for several metabolic disorders. The aim was to evaluate the efficacy of the pan-PPAR agonist, bezafibrate, in tafazzin knockdown mice (TazKD), a mouse model of Bart
Autor:
Khuchua Zaza, Danny V. Jeyaraju, Mingjing Xu, Neil MacLean, Ayesh K. Seneviratne, Zhenyue Hao, Juan J. Aristizabal Henao, Rose Hurren, Steven M. Claypool, Xioaming Wang, Paul J. LeBlanc, Raphaël Chouinard-Watkins, Aaron D. Schimmer, Val Fajado, Ken D. Stark, Richard P. Bazinet, G. Wei Xu, Sejin Kim, Marcela Gronda, Caitlin Schafer
Publikováno v:
Blood. 130:788-788
AML cells have unique mitochondrial characteristics with an increased reliance on mitochondrial metabolism and oxidative phosphorylation. To identify new biological vulnerabilities in the mitochondria of AML, we conducted a CRISPR knockout screen. CA